Argenx
ARGX
#439
Rank
$56.80 B
Marketcap
$909.03
Share price
3.57%
Change (1 day)
68.10%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

P/E ratio for Argenx (ARGX)

P/E ratio as of June 2026 (TTM): 57.5

According to Argenx 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 57.4579. At the end of 2025 the company had a P/E ratio of 39.7.

P/E ratio history for Argenx from 2018 to 2026

PE ratio at the end of each year

Year P/E ratio Change
202539.7-10.75%
202444.5-160.41%
2023-73.7153.98%
2022-29.0-34.3%
2021-44.298.94%
2020-22.2-35.11%
2019-34.2-26.63%
2018-46.61.05%
2017-46.2

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.